Entering text into the input field will update the search result below

Sanofi, Regeneron sue Amgen over eczema drug

Mar. 21, 2017 1:38 PM ETSanofi (SNY) StockAMGN, SNY, REGNBy: Stephen Alpher, SA News Editor10 Comments
  • At issue is whether Sanofi's (SNY +0.2%) and Regeneron's (REGN -1.3%) Dupixent - currently awaiting U.S. approval (expected next week) - infringes on an Amgen (AMGN -1.3%) patent for a failed asthma treatment.
  • The lawsuit filed by the duo today preempts what is expected to be one brought by Amgen (which recently received a favorable ruling in its lawsuit against the two over Praluent).
  • Annual sales for Dupixent are predicted to top $5B by 2023.

Recommended For You

About SNY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SNY--
Sanofi